NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
NuCana plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026
$0.98−0.01 (-1.30%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
NuCana has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements NuCana filed with the SEC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
NuCana Appoints Ian Webster as Chief Financial Officer
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and
EX-99.1 to Form 6-K
NuCana Appoints Theresa Bruce as Chief Operating Officer
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
NuCana Reports Third Quarter 2025 Financial Results and Provides Business
EX-99.3 to Form 6-K
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
EX-99.1 to Form 6-K
NuCana Presents Encouraging Data on NUC-7738 in Combination with
EX-99.1 to Form 6-K
NuCana Compliant with All Nasdaq Continued Listing Criteria
EX-99.1 to Form 6-K
NuCana to Present Data on NUC-7738’s Synergy with PD-1
EX-99.1 to Form 6-K
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
NuCana Announces ADS Ratio Change
EX-99.1 to Form 6-K
NuCana Announces Plan to Implement ADS Ratio Change
EX-99.1 to Form 6-K
Adam George (retired 21 March 2025)
EX-99.2 to Form 6-K
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
EX-99.1 to Form 6-K
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study
EX-99.1 to Form 6-K
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738
EX-99.1 to Form 6-K